^
Association details:
| Biomarker: | EGFR exon 20 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.
Published date:
05/16/2018
Excerpt:
Compared to classic EGFR mutants, EGFR exon 20 mutants demonstrated a higher disease control rate at 6 and 12 months as well as higher ORR. Also, EGFR exon 20 mutants demonstrated significantly higher PFS (HR 0.45, p = 0.002) and OS (HR 0.2, p < 0.001)...EGFR exon 20 mutations are associated with superior outcome from immune checkpoint inhibitors compared to classic EGFR and HER-2 exon 20 mutations.
DOI:
10.1200/JCO.2018.36.15_suppl.9052
